Nova In Silico leverages advanced in silico modeling technologies to enhance the efficiency and effectiveness of clinical trials. Their flagship platform, jinkō, utilizes virtual population simulations and mechanistic modeling to predict clinical outcomes before human trials commence. By creating detailed disease and treatment models, Nova can simulate various clinical scenarios, allowing researchers to identify optimal treatment combinations and trial designs. This approach not only accelerates the drug development process but also significantly reduces the risk to human subjects by improving trial design and minimizing the number of necessary experiments.

The company’s methodology involves constructing knowledge-based models that encapsulate the physiological and clinical impacts of diseases and treatments. These models are built from extensive literature reviews, where relevant data is extracted and rated for evidence strength. This structured knowledge is then translated into mathematical equations, enabling the simulation of disease progression and treatment effects on virtual patients. By employing this innovative technology, Nova In Silico aims to streamline the entire research and development process, from discovery through to market access, ultimately facilitating faster insights and better outcomes in clinical trials.

France

Nova provides its jinkō clinical trials simulation platform to biotech and pharma companies, academic research centers and not-for-profit organizations.

Jinkō® unlocks the potential of modeling & simulation to de-risk and accelerate the R&D of new therapies for the benefit of patients: identify best responders, optimise the drug's regimen, generate synthetic control arms, explore research outcomes that might not be feasible with conventional trials.

Predict trial outcomes before advancing to real-world clinical trials and ultimately design studies that are more likely to succeed with Jinkō®.

Nova In Silico

Company Details